Interleukin Genetics licenses PST Genetic Test to OralDNA Labs

WALTHAM, Massachusetts, and BRENTWOOD, Tennessee--Interleukin Genetics, Inc., and OralDNA Labs, Inc., has announced the execution of a marketing, sales and distribution agreement for Interleukin Genetics' proprietary PST Genetic Test.

The PST Genetic Test provides a means of assessing an individual's genetic risk for periodontal disease, the most common cause of tooth loss. Under the terms of the agreement, OralDNA will receive a non-exclusive license from Interleukin Genetics to market, sell and distribute Interleukin Genetics' proprietary PST Genetic Test to dental practices within the United States.

OralDNA will pay Interleukin Genetics a set fee per test for all tests sold by OralDNA and is responsible for all costs it incurs for marketing such tests. Patients will be asked in the informed consent if they would like to receive additional testing services, other than the PST Genetic Test, provided by Interleukin Genetics.

Lewis H. Bender, chief executive officer of Interleukin Genetics, commented, "We are pleased to have entered into this license agreement for OralDNA to market our PST Genetic Test as a determinant of risk for periodontal disease. We believe that this relationship will allow our sales of this important product to grow with a sales force that specifically targets dental practices. In addition, we expect that this agreement with OralDNA Labs will enable our core strategy of growth through partnerships and should allow Interleukin Genetics to build a customer base to provide additional test services."

Brian C. Carr, chief executive officer of OralDNA, commented, "We are very excited to be working with Interleukin Genetics and adding the PST Genetic Test to our portfolio of diagnostic tests performed in our new U.S. based laboratory. We believe that by combining our MyPerioPath test, which identifies specific pathogenic bacteria causing an infection within the gum structure, with the PST Genetic Test, we are providing the dental community with the proper tools to identify and treat periodontal disease. The combination of both tests creates a systematic way to track and maximize clinical outcomes for dental professionals and their patients. As we continue to understand the systemic link and risk factors associated with periodontal disease, it's important that we partner with companies who, like us, are focused on helping dental professionals identify and treat disease at its earliest onset."

For more information about Interleukin Genetics, its products and ongoing programs, visit Interleukin Genetics.

To read more about Interleukin Genetics, go to Interleukin Genetics.

To comment on this topic, go to PennWell Dental Community site.